Metabolic surgery versus conventional therapy in type 2 diabetes

Alexander D. Miras, Carel W. le Roux

Research output: Contribution to journalComment/debatepeer-review

4 Citations (Scopus)
Original languageEnglish
Pages (from-to)256-257
Number of pages2
JournalThe Lancet
Issue number10271
Publication statusPublished (in print/issue) - 23 Jan 2021

Bibliographical note

Funding Information:
CWlR declares grant funding from Science Foundation Ireland (12/YI/B2480), the Health Research Board (USIRL-2016-2), and the Irish Research Council (IRCLA/2017/234) in the area of type 2 diabetes. CWlR serves on advisory boards for Novo Nordisk, Herbalife, Boehringer Ingelheim, Johnson & Johnson, Keyron, AnaBio, and Sanofi, outside of the area of work commented on here. ADM declares no competing interests.


  • Bariatric Surgery
  • Diabetes Mellitus, Type 2/drug therapy
  • Follow-Up Studies
  • Glycated Hemoglobin A/analysis
  • Humans

Cite this